Number of pages: 100 | Report Format: PDF | Published date: March 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global non-muscle-invasive bladder cancer market was valued at US$ 2.9 billion in 2021 and is expected to register a revenue CAGR of 6.5% to reach US$ 5.5 billion by 2031.
Non-muscle-invasive Bladder Cancer Market Fundamentals
Non-muscle invasive bladder cancer (NMIBC) develops in the bladder lining, and the bladder muscle is not involved. Bladder cancer ranks sixth among all cancers in the United States. It accounts for about 75% of all bladder cancer cases and is generally considered to have a good prognosis. However, the risk of recurrence is high, and patients require close monitoring and frequent follow-up examinations. According to the American Cancer Society, more than 81,000 people in the United States were estimated to be diagnosed with bladder cancer by 2020. Males are more likely to develop bladder cancer than females. The risk factors associated with NMIBC include smoking, cigarette smokers are up to three times more likely than non-smokers to develop bladder cancer; old age, most people with bladder cancer are over 60, and the risk increases with age; and being male, men are three to four times more likely than women to develop bladder cancer. NMIBC accounts for 70%-75% of all bladder malignancies. The development of innovative medicines and favorable government policies indicate the need and presence of a robust pipeline for NMIBC therapeutics.
Non-muscle-invasive Bladder Cancer Market Dynamics
The global non-muscle-invasive bladder cancer therapeutics market is expected to expand rapidly during the forecast period, owing to an increase in the incidence and prevalence of bladder cancer, advancements in healthcare services, and technological developments in the bladder cancer detection system, all of which are driving high demand for treatment. Furthermore, the rising elderly population and growing need for effective treatments are expected to augment the revenue growth of the global non-muscle-invasive bladder cancer therapeutics market.
Non-muscle-invasive Bladder Cancer Market Ecosystem
The global non-muscle-invasive bladder cancer market has been analyzed from three perspectives: treatment type, end user, and region.
Non-muscle-invasive Bladder Cancer Market by Treatment Type
Based on the treatment type, the global non-muscle-invasive bladder cancer market has been segmented into immunotherapy, chemotherapy, and targeted therapy.
Bacillus Calmette-Guérin (BCG) and pembrolizumab are the major immunotherapies, whereas chemotherapies include anthracyclines, mitomycin C, and gemcitabine. The chemotherapy segment is expected to dominate the market, and immunotherapy is projected to emerge as the fastest-growing segment during the forecast period. Chemotherapy is in high demand in NMIBC as it is an effective treatment option for many patients. Chemotherapy drugs are typically administered directly into the bladder, allowing a higher concentration of the drug to be delivered to cancerous cells while minimizing side effects in other areas of the body.
NMIBC is treated with various chemotherapy drugs, including mitomycin C and gemcitabine. These medications work by causing DNA damage in cancer cells, preventing them from dividing and growing. Chemotherapy can also help to lower the likelihood of cancer returning after treatment.
The usage of chemotherapy in NMIBC is determined by several factors, including cancer’s stage and grade and the patient’s overall health. While chemotherapy is an effective treatment for NMIBC, it may not be appropriate for all patients. Some patients may benefit from alternative treatments, such as immunotherapy. Ultimately, there is a high demand for chemotherapy in NMIBC, and it is an important treatment option for many patients.
Non-muscle-invasive Bladder Cancer Market End User
Based on end user, the global non-muscle-invasive bladder cancer market has been segmented into hospitals, cancer specialty centers, and others (ambulatory care centers, clinics, etc.).
The hospitals segment is expected to dominate the market during the forecast period. The segment growth can be attributed to the growing number of patients visiting hospitals for cancer diagnosis and treatment and the favorable reimbursement scenario, especially in the developed markets.
Non-muscle-invasive Bladder Cancer Market by Region
Based on region, the global non-muscle-invasive bladder cancer market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
With a favorable reimbursement environment, North America is projected to continue leading the non-muscle invasive bladder cancer market in the following decade. The increased prevalence rate of bladder cancer enhances North America’s demand for NMIBC treatments.
Europe is the second leading regional market for NMIBC therapies due to the availability of modern technologies and a big aging population.
Asia Pacific is lucrative, with a higher growth rate in the non-muscle invasive bladder cancer market during the forecast period owing to the region’s rising disease prevalence and diagnosis rates. The growing number of domestic players in Asia Pacific makes the non-muscle invasive bladder cancer market attractive.
The Middle East and Africa market is likely to experience the slowest growth due to limited access to healthcare in the region. The uptake of traditional therapies, such as chemotherapy, shall be the mainstay in the Middle East and Africa markets.
Non-muscle-invasive Bladder Cancer Market Competitive Landscape
The prominent market players in the global non-muscle-invasive bladder cancer market include:
The non-muscle-invasive bladder cancer market is highly competitive, with several companies offering various products and services for diagnosing, treating, and managing this disease. Ferring Pharmaceuticals, a Swiss-based company specializing in urology and gastroenterology, is a key player in the non-muscle-invasive bladder cancer market. Instillagel, a product developed by Ferring, is used to lubricate the urethra during cystoscopy and other procedures. This reduces discomfort and the possibility of complications. Instillagel is widely used in hospitals and clinics worldwide and is considered a standard of care for many urology procedures. Ferring is also working on a new product called Citanest, a local anesthetic used to numb the bladder during cystoscopy and other procedures. Citanest is expected to reduce the need for general anesthesia while improving patient comfort during procedures.
Becton, Dickinson, and Company (BD), an American medical technology company, is another major player in the non-muscle-invasive bladder cancer market. The BD BCG vaccine is developed by BD that stimulates the immune system and prevents the recurrence of non-muscle-invasive bladder cancer. The BD BCG vaccine is a live, attenuated strain of Mycobacterium bovis administered directly into the bladder. It is one of the most effective treatments for non-muscle-invasive bladder cancer. It is used with other treatments, such as surgery and chemotherapy. Merck & Co., Pfizer Inc., and Sanofi S.A. are also players in the NMIBC market. Merck & Co. manufactures a drug known as Bacillus Calmette-Guérin (BCG), similar to the BD BCG vaccine but developed using a different strain of Mycobacterium bovis. Valstar, a drug manufactured by Pfizer, is used to treat early-stage NMIBC. Sanofi manufactures Javlor, a drug used to treat advanced bladder cancer.
Companies are also differentiating themselves by providing superior customer service and support. This includes providing educational materials and resources to patients and healthcare providers and training and support for their products’ usage. Companies building strong relationships with their customers have resulted in improved chances of increasing revenue share in the non-muscle-invasive bladder cancer market.
Europe is the key revenue growth region in the global non-muscle-invasive bladder cancer market.
The rise in the prevalence of NMIBC due to the rise in unhealthy habits, the increase in the geriatric population, and technological advancements in the diagnosis of bladder cancer are propelling revenue growth in the global market.
Merck & Co., Inc., Lilly USA, LLC, Sun Pharmaceutical Industries, Inc., Pfizer Inc., and Ferring B.V. are among the top market players.
The global non-muscle-invasive bladder cancer market is estimated to be valued at US$ 5.5 billion by 2031.
The global non-muscle-invasive bladder cancer market is estimated to grow at a revenue CAGR of 6.5% during the forecast period from 2023 to 2031.
*Insights on financial performance is subject to availability of information in public domain